Tag - CLAZF

Feature

Claritas Pharmaceuticals transforming nitric oxide therapy

Claritas Pharmaceuticals (TSXV:CLAS; OTC:CLAZF) is developing R-107, a liquid drug candidate that may hold the key to transforming nitric oxide therapy from its current gaseous inhalation method of delivery to...

April 26, 2022

Developments

Australian committee approves Claritas Phase 1 trial of R-107

The Australian Human Research Ethics Committee has approved Claritas Pharmaceuticals’ (TSXV:CLAS; OTC:CLAZF) submission for the Phase 1 clinical study of R-107 to be conducted at Scientia Clinical Research in Sydney...

April 5, 2022

Tag - CLAZF

Claritas Pharmaceuticals transforming nitric oxide therapy

Australian committee approves Claritas Phase 1 trial of R-107

General

More